Profile data is unavailable for this security.
About the company
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
- Revenue in USD (TTM)285.82m
- Net income in USD-58.56m
- Incorporated2012
- Employees329.00
- LocationEvolus Inc520 Newport Center Dr Ste 1200NEWPORT BEACH 92660-7022United StatesUSA
- Phone+1 (949) 284-4555
- Fax+1 (302) 636-5454
- Websitehttps://www.evolus.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp | 10.30m | -99.22m | 193.70m | 81.00 | -- | 0.666 | -- | 18.81 | -20.11 | -20.11 | 1.69 | 22.73 | 0.0593 | 0.9665 | 2.75 | 127,148.10 | -57.12 | -61.84 | -63.76 | -68.67 | 34.31 | -- | -963.38 | -2,797.35 | 9.62 | -- | 0.00 | -- | 29.94 | -- | -11.47 | -- | 47.82 | -- |
| Coherus Oncology Inc | 83.57m | -187.47m | 194.60m | 161.00 | -- | 2.13 | -- | 2.33 | -1.62 | 1.33 | 0.721 | 0.7551 | 0.1636 | 1.76 | 0.9453 | 366,526.30 | -36.70 | -21.44 | -106.02 | -31.54 | 47.79 | 71.26 | -224.34 | -42.66 | 1.23 | -15.12 | 0.3656 | -- | 3.78 | -5.60 | 111.98 | -20.51 | -- | -- |
| Journey Medical Corp | 59.40m | -8.66m | 210.69m | 41.00 | -- | 7.87 | -- | 3.55 | -0.3645 | -0.3645 | 2.58 | 0.982 | 0.796 | 1.79 | 4.15 | 1,448,756.00 | -11.61 | -22.37 | -22.74 | -50.55 | 64.40 | 59.45 | -14.58 | -27.43 | 1.12 | -3.30 | 0.4928 | -- | -29.11 | 9.96 | -280.79 | -- | 44.27 | -- |
| Mediwound Ltd | 20.93m | -20.60m | 221.66m | 111.00 | -- | 4.41 | -- | 10.59 | -1.90 | -1.90 | 1.93 | 3.91 | 0.2475 | 4.59 | 3.69 | 188,576.60 | -24.36 | -35.38 | -35.12 | -48.39 | 18.53 | 32.18 | -98.43 | -71.55 | 2.48 | -- | 0.1416 | -- | 8.22 | -8.65 | -350.03 | -- | 51.27 | -- |
| Opus Genetics Inc | 14.63m | -68.20m | 251.03m | 18.00 | -- | 39.37 | -- | 17.16 | -1.76 | -1.76 | 0.2952 | 0.0925 | 0.3825 | -- | 3.85 | 812,944.40 | -178.28 | -76.30 | -330.00 | -86.90 | -- | -- | -466.09 | -185.79 | -- | -- | 0.1518 | -- | -42.30 | -- | -476.13 | -- | -- | -- |
| Lifecore Biomedical Inc | -100.00bn | -100.00bn | 265.26m | 406.00 | -- | -- | -- | -- | -- | -- | -- | 0.9818 | -- | -- | -- | -- | -- | -7.91 | -- | -10.85 | -- | 32.86 | -- | -23.15 | 1.67 | -- | 0.787 | -- | 0.4725 | -4.24 | -575.39 | -- | -12.85 | -- |
| Abeona Therapeutics Inc | 400.00k | 82.35m | 271.50m | 136.00 | 4.53 | 1.53 | 3.21 | 678.75 | 1.11 | 1.11 | 0.0073 | 3.27 | 0.0023 | -- | 0.2478 | 2,941.18 | 46.83 | -62.23 | 52.94 | -78.23 | -122.00 | -- | 20,587.50 | -1,824.21 | 9.53 | -- | 0.1034 | -- | -100.00 | -- | -17.62 | -- | -17.78 | -- |
| Evolus Inc | 285.82m | -58.56m | 278.73m | 329.00 | -- | -- | -- | 0.9752 | -0.9125 | -0.9125 | 4.46 | -0.4441 | 1.27 | 4.09 | 6.01 | 860,912.60 | -26.11 | -37.04 | -36.48 | -57.14 | 65.83 | 65.19 | -20.49 | -51.26 | 1.53 | -2.13 | 1.25 | -- | 31.76 | 50.12 | 18.26 | -- | 1.10 | -- |
| Fennec Pharmaceuticals Inc | 38.79m | -6.94m | 287.57m | 36.00 | -- | -- | -- | 7.41 | -0.2524 | -0.2524 | 1.41 | -0.1601 | 0.7171 | 1.48 | 2.41 | -- | -12.83 | -55.15 | -15.26 | -64.98 | 93.12 | -- | -17.89 | -107.31 | 4.44 | -2.44 | 1.33 | -- | 123.69 | -- | 97.28 | -- | -- | -- |
| X4 Pharmaceuticals Inc | 33.98m | -95.10m | 298.16m | 143.00 | -- | 1.39 | -- | 8.77 | -10.50 | -10.50 | 2.94 | 2.45 | 0.1989 | 1.75 | 25.37 | 237,615.40 | -55.66 | -55.04 | -65.82 | -63.45 | 83.24 | -- | -279.86 | -6,897.81 | 5.48 | -19.26 | 0.5525 | -- | -- | -- | 62.98 | -- | 111.28 | -- |
| AC Immune SA | 5.70m | -93.66m | 300.23m | 133.00 | -- | 3.69 | -- | 52.70 | -0.932 | -0.932 | 0.0567 | 0.8104 | 0.021 | -- | 0.3392 | 42,835.79 | -34.57 | -27.41 | -66.37 | -30.60 | -- | -- | -1,643.94 | -505.58 | -- | -- | 0.0695 | -- | 84.51 | -24.38 | 6.12 | -- | -21.11 | -- |
| Akebia Therapeutics Inc | 225.07m | -15.91m | 321.09m | 181.00 | -- | 7.72 | -- | 1.43 | -0.0761 | -0.0761 | 0.8951 | 0.1568 | 0.7879 | 2.08 | 4.57 | 1,243,486.00 | -5.57 | -38.92 | -8.55 | -61.07 | 81.89 | 71.93 | -7.07 | -76.49 | 1.80 | 0.7147 | 0.8219 | -- | -17.70 | -13.72 | -33.67 | -- | -65.40 | -- |
| Puma Biotechnology Inc | 212.00m | 36.98m | 343.67m | 172.00 | 9.20 | 2.98 | 7.14 | 1.62 | 0.7414 | 0.7414 | 4.23 | 2.29 | 1.00 | 8.06 | 4.81 | 1,232,529.00 | 17.46 | -3.25 | 32.09 | -5.70 | 76.91 | 75.67 | 17.44 | -3.18 | 1.62 | 8.84 | 0.2263 | -- | -2.19 | -3.28 | 40.23 | -- | -28.80 | -- |
Data as of Feb 13 2026. Currency figures normalised to Evolus Inc's reporting currency: US Dollar USD
46.33%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nantahala Capital Management LLCas of 31 Dec 2025 | 5.82m | 9.00% |
| Tang Capital Management LLCas of 30 Sep 2025 | 5.49m | 8.49% |
| Caligan Partners LPas of 30 Sep 2025 | 4.14m | 6.40% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 3.70m | 5.73% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.89m | 4.47% |
| Millennium Management LLCas of 30 Sep 2025 | 1.86m | 2.87% |
| Stonepine Capital Management LLCas of 31 Dec 2025 | 1.63m | 2.52% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 1.57m | 2.44% |
| Eversept Partners LPas of 30 Sep 2025 | 1.48m | 2.28% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.39m | 2.14% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
